Daniel S. Bradford

470 total citations
12 papers, 373 citations indexed

About

Daniel S. Bradford is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hepatology. According to data from OpenAlex, Daniel S. Bradford has authored 12 papers receiving a total of 373 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 2 papers in Hepatology. Recurrent topics in Daniel S. Bradford's work include Lung Cancer Treatments and Mutations (9 papers), Lung Cancer Research Studies (6 papers) and Lung Cancer Diagnosis and Treatment (5 papers). Daniel S. Bradford is often cited by papers focused on Lung Cancer Treatments and Mutations (9 papers), Lung Cancer Research Studies (6 papers) and Lung Cancer Diagnosis and Treatment (5 papers). Daniel S. Bradford collaborates with scholars based in United States, Czechia and Canada. Daniel S. Bradford's co-authors include James S. Zoller, Paul J. Nietert, Gerard A. Silvestri, Diane Healey, Petr Zatloukal, Dae Seog Heo, Jaewon Kang, K. Park, Stephen L. Graziano and Mark A. Socinski and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Thorax.

In The Last Decade

Daniel S. Bradford

11 papers receiving 366 citations

Peers

Daniel S. Bradford

ONCOL

PRM

IMMUN

OTORH

Hilary S. Serracino United States

Carmen Salvador Coloma Spain

Jia-Wei Lv China

Mandar Karhade United States

Cornedine J. de Gooijer Netherlands

Jiebai Zhou China

Linpeng Zheng China

Aaron E. Sosa Spain

Eve‐Marie Neidhardt France

Grégoire Marret France

Hilary S. Serracino United States

Daniel S. Bradford

189 ×0.7

ONCOL

96 ×0.4

PRM

65 ×1.0

IMMUN

65 ×1.1

62 ×1.9

OTORH

Citations per year, relative to Daniel S. Bradford Daniel S. Bradford (= 1×) peers Hilary S. Serracino

Countries citing papers authored by Daniel S. Bradford

Since Specialization

Citations

This map shows the geographic impact of Daniel S. Bradford's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel S. Bradford with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel S. Bradford more than expected).

Fields of papers citing papers by Daniel S. Bradford

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel S. Bradford. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel S. Bradford. The network helps show where Daniel S. Bradford may publish in the future.

Co-authorship network of co-authors of Daniel S. Bradford

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel S. Bradford. A scholar is included among the top collaborators of Daniel S. Bradford based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel S. Bradford. Daniel S. Bradford is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Bauer, Michael, J. Thaddeus Beck, Daniel S. Bradford, et al.. (2023). Increased Utilization of Low-Dose CT for Lung Cancer Screening at an Arkansas Community Oncology Clinic. Journal of the American College of Radiology. 21(6). 858–866. 1 indexed citations

Weiss, Jared, Nathan A. Pennell, Allison M. Deal, et al.. (2020). Nab‐paclitaxel in older patients with non–small cell lung cancer who have developed disease progression after platinum‐based doublet chemotherapy. Cancer. 126(5). 1060–1067. 12 indexed citations

Awad, Mark M., Leena Gandhi, Joe Stephenson, et al.. (2016). An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC). Lung Cancer. 104. 126–130. 47 indexed citations

Stinchcombe, Thomas E., Amy H. Peterman, Carrie B. Lee, et al.. (2011). A Randomized Phase II Trial of First-Line Treatment with Gemcitabine, Erlotinib, or Gemcitabine and Erlotinib in Elderly Patients (Age ≥70 Years) with Stage IIIB/IV Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 6(9). 1569–1577. 30 indexed citations

Harb, Wael A., Daniel S. Bradford, José A. Bufill, et al.. (2010). Randomized, Double-Blinded, Multicenter, Phase II Study of Pemetrexed, Carboplatin, and Bevacizumab with Enzastaurin or Placebo in Chemonaïve Patients with Stage IIIB/IV Non-small Cell Lung Cancer: Hoosier Oncology Group LUN06-116. Journal of Thoracic Oncology. 5(11). 1815–1820. 23 indexed citations

Stinchcombe, Thomas E., Daniel S. Bradford, Dominic T. Moore, et al.. (2010). Preliminary results of a randomized phase II trial of first-line treatment of gemcitabine (G) versus erlotinib (E) versus gemcitabine and erlotinib (GE) in patients 70 years or older with advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 28(15_suppl). 7576–7576. 3 indexed citations

Stinchcombe, Thomas E., Daniel S. Bradford, Thomas A. Hensing, et al.. (2009). A Multicenter Phase II Trial of Carboplatin and Cetuximab for Treatment of Advanced Nonsmall Cell Lung Cancer. Cancer Investigation. 28(2). 208–215. 7 indexed citations

Harb, Wael A., Daniel S. Bradford, José A. Bufill, et al.. (2009). Randomized, double blind, multicenter, phase II study of pemetrexed (PEM), carboplatin (CARBO), bevacizumab (BEV) with enzastaurin (ENZ) or placebo (PBO) in chemotherapy-naive patients with stage IIIB/IV non-small cell lung cancer (NSCLC): Hoosier Oncology Group (HOG) LUN06–116. Journal of Clinical Oncology. 27(15_suppl). 8035–8035. 8 indexed citations

Zatloukal, Petr, Dae Seog Heo, K. Park, et al.. (2009). Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 27(15_suppl). 8071–8071. 104 indexed citations

10.

Ansari, Rafat, Mark A. Socinski, J. K. Choksi, et al.. (2008). A phase II, multicenter evaluation of docetaxel, gemcitabine, and bevacizumab followed by bevacizumab alone in patients with locally advanced or metastatic non-small cell lung cancer (central localization excluded). Journal of Clinical Oncology. 26(15_suppl). 19077–19077.

11.

Bradford, Daniel S., Mark A. Socinski, R. V. Larocca, Thomas A. Hensing, & Rodolfo Bordoni. (2007). Phase II trial of carboplatin plus cetuximab for the treatment of stage IIIB/IV non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 25(18_suppl). 18005–18005. 5 indexed citations

12.

Silvestri, Gerard A., et al.. (2006). Attitudes towards screening for lung cancer among smokers and their non-smoking counterparts. Thorax. 62(2). 126–130. 133 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact